TheraRadar
← Back
Data updated: Nov 8, 2026

PTC Therapeutics

Biotech
RespiratoryOncologyNeurology Execution: Fair

PTC Therapeutics is a biotechnology company focused on Respiratory, Oncology, Neurology. Key products include KEBILIDI.

2024
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics

PTC Therapeutics at a Glance

  • Fast trial execution (26 months median completion)

PTC Therapeutics's Key Drugs

PTC Therapeutics's core commercial portfolio centers on KEBILIDI, spanning Respiratory and Oncology — its most strategically important drugs approved in the last 15 years.

KEBILIDI
DDC Approved 2024

PTC Therapeutics's Recent FDA Approvals

New NDA/BLA approvals for PTC Therapeutics over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PTC Therapeutics's Therapeutic Areas

PTC Therapeutics's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Oncology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 65%
0 drugs Phase 3: 5
Oncology 19%
0 drugs Phase 2: 1 Phase 1: 4
Neurology 6%
0 drugs Phase 2: 1
Immunology 6%
0 drugs Phase 2: 1
Gastroenterology 3%
0 drugs Phase 1: 1

PTC Therapeutics's Top Competitors

PTC Therapeutics's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Neurology
Pfizer big-pharma
Oncology, Immunology, Neurology
Novartis big-pharma
Oncology, Respiratory, Immunology
AbbVie big-pharma
Immunology, Oncology, Neurology
Johnson & Johnson big-pharma
Oncology, Immunology, Gastroenterology

PTC Therapeutics Pipeline Snapshot

PTC Therapeutics has 13 active clinical programs from ClinicalTrials.gov — 5 Phase 3, 3 Phase 2 and 5 Phase 1.

5
Phase 3
3
Phase 2
5
Phase 1

Phase 3 Readout Calendar Pro

1 Phase 3 trial with confidence-graded primary completion dates.

Full calendar →
Q4 2027
Vatiquinone
Friedreich Ataxia
Estimated · aging NCT05515536

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • KEBILIDI leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Respiratory pipeline focus
  • • 1 Phase 3 readout tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 9/17 completed
  • • Speed: 26 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges